hypertension
Conditions
Interventions
hypertension study group: ARNI :None
hypertension control group: valsartan:None
Sponsors
The First Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Age
31 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the HHD group: 1. age 18-75 years old and gender; 2. previous history of hypertension with clinical diagnosis of HHD: no antihypertensive medication, office blood pressure (systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg); combined with the following (1) signs or symptoms of heart failure; and/or (2) confirmed cardiac enlargement, diagnostic criteria of echocardiography: left ventricular hypertrophy and enlargement, enlarged left atrium, aortic hypoelasticity, and A-peak > E-peak (A Echocardiographic diagnostic criteria: left ventricular hypertrophy, enlargement, left atrial enlargement, aortic hypoelasticity, peak A > peak E (A > E), can diagnose HHD; 3. echocardiographic measurement of cardiac data left ventricular ejection fraction (LVEF) =50%; 4. systolic blood pressure 35 mm; b. left atrial volume index >21 ml/m2 (men) and left atrial volume index >22 ml/m2 (women); and/or septal thickness or left ventricular posterior wall thickness =1.1 cm and =2.5 cm), corrected for the actual situation in China; 6. patients volunteered to participate in the study and their informed consent was obtained; 7. the control group was selected to match the study group in terms of gender and age, etc. HHD without other heart diseases and other causes of ventricular hypertrophy and diastolic dysfunction after inquiring about the medical history and relevant examinations;
Exclusion criteria
Exclusion criteria: Exclusion criteria for HHD group: 1. physiologic left atrial volume increase in athletes; 2. patients with history of angioedema, estimated glomerular filtration rate (eGFR) 145 mmol/L) or potassium concentrations (5.5 mmol/L); 5. life-threatening or uncontrolled arrhythmias, including symptomatic or sustained ventricular tachycardia and atrial fibrillation or atrial flutter with a resting ventricular rate >110 beats per minute;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left ventricular diastolic function;Short range heart rate variability; | — |
Secondary
| Measure | Time frame |
|---|---|
| Baseline indicators: blood pressure, weight, uric acid, etc; | — |
Countries
China
Contacts
Public ContactHouyuan Hu
The First Affiliated Hospital of the Army Medical University
Outcome results
None listed